The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Anne Månsson Kvarnhammar
Alligator Bioscience AB
January 1, 2019
J Immunother Cancer
https://pubmed.ncbi.nlm.nih.gov/30975201

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/30975201

Research summary

This study introduces ATOR-1015, a human IgG1 bispecific antibody targeting CTLA-4 and OX40, designed to enhance tumor-directed immune activation. In vitro assays demonstrated that ATOR-1015 effectively activates T cells and depletes regulatory T cells (Tregs). In vivo, using human OX40 transgenic (Knockin) mice with established syngeneic tumors, ATOR-1015 treatment reduced tumor growth, improved survival, and induced long-term immunological memory. The antibody localized to the tumor microenvironment, decreased Treg frequency, and increased the number and activation of CD8+ T cells. Additionally, ATOR-1015 enhanced responses to PD-1 inhibition, suggesting its potential as a next-generation CTLA-4 targeting therapy with improved efficacy and reduced toxicity.

Key outcome of the study

ATOR-1015 induces T-cell activation and Treg depletion, reduces tumor growth, improves survival, and enhances the response to PD-1 inhibition in multiple syngeneic tumor models.

Model

Human OX40 transgenic (Knockin) mice with established syngeneic tumors

TARGET:
CTLA4, TNFRSF4
Synonyms:
CTLA-4, OX40

Keywords

Cancer immunotherapy, Bispecific antibody, CTLA-4, OX40, Treg depletion, T-cell activation

Technical specifications

Human OX40 transgenic Knockin model, Syngeneic tumor models, Bispecific antibody therapy

Related products

Catalogue product

genO-hOX40

The genO-hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

Customized product

No items found.

Catalogue product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe